<DOC>
	<DOCNO>NCT00749580</DOCNO>
	<brief_summary>The purpose study determine whether raltegravir 400 mg b.i.d . boost PI regimen efficacious safe NRTI backbone boost PI regimen .</brief_summary>
	<brief_title>A Pilot , Raltegravir Versus NRTIs Backbone Switched From Stable Boosted PI Regimen</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>1 . Patient male female least 18 year age day sign informed consent . 2 . Patient HIV positive determine enzymelinked immunosorbent assay ( ELISA ) HIV PCR . 3 . Patient document HIV RNA &lt; 75 copies/mL least 3 month prior study entry stable boost PI base regimen without change antiretroviral therapy documentation HIV RNA &gt; = 75 copies/mL time . 4 . Patient history document coronary artery disease clinical investigator deem clinically significant . 5 . Patient follow laboratory value within 35 day prior treatment phase study : Alkaline phosphatase ≤ 5.0 x upper limit normal AST ( SGOT ) ALT ( SGPT ) ≤ 5.0 x upper limit normal . Patients Hepatitis C Coinfection may enrol provide patient stable meet eligibility criterion . 6 . Patient clinical evidence active pulmonary disease ; investigator , discretion chest xray could obtain felt necessary . 7 . Patient reproductive potential agrees use acceptable method birth control throughout study . 8 . Patient agree remain prohibited concomitant medication outline Section 3.2.1 protocol . 1 . Patients currently fail boost PI base regimen . 2 . Patient receive second line boost PI regimen include boost tripranavir boost darunavir . 3 . Patients chronic hepatitis B infection . 4 . Patient history current evidence condition , therapy , laboratory abnormality circumstance might confound result study , interfere patient 's participation full duration study , best interest patient participate . 5 . Patient history alcohol substance abuse opinion investigator would interfere patient compliance safety . 6 . Patient currently participate participate study investigational compound device within 30 day sign informed consent . 7 . Patient ever use experimental HIVintegrase inhibitor . 8 . Patient use systemic immunosuppressive therapy ( e.g. , 20 mg prednisone equivalent per day ) within one month prior treatment study . Short course corticosteroid ( e.g. , asthma exacerbation ) allow . 9 . Patient require hemodialysis . 10 . Patient significant hypersensitivity contraindication component study drug . 11 . Patient chronic hepatitis , include chronic hepatitis B and/or C decompensated liver disease . 12 . Patient pregnant breastfeeding , expect conceive ( within duration study ) . Patient expect donate egg ( within duration study ) . Patient expect donate sperm ( within duration study ) . 13 . Subjects receive investigational medication within 30 day baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Safety</keyword>
</DOC>